Insider · CIK 0001758363
Cameron Turtle
ceoofficerdirector
Files at ORKA (Oruka Therapeutics, Inc.), SYRE (Spyre Therapeutics, Inc.), DMRA (Galecto, Inc.). First filing Nov 5, 2025, latest Oct 2, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 7
$0 bought, $5.8M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SYRE: Spyre Therapeutics, Inc.
SYREOct 9, 2026 · close 85.69
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | Spyre Therapeutics, Inc. | $1.4M 15,000 shares | -3% | +466% from low-17% from high | |
| 45Moderate | Spyre Therapeutics, Inc. | $1.3M 15,000 shares | -3% | +497% from low-19% from high | |
| 33Weak | Spyre Therapeutics, Inc. | $633k 15,000 shares | -2% | +260% from low-4% from high | |
| 23Weak | Spyre Therapeutics, Inc. | $492k 15,000 shares | -2% | +178% from low-6% from high | |
| 22Weak | Spyre Therapeutics, Inc. | $460k 15,000 shares | -2% | +159% from low-12% from high | |
| 22Weak | Spyre Therapeutics, Inc. | $435k 15,000 shares | -2% | +143% from low-4% from high | |
| 30Weak | Spyre Therapeutics, Inc. | $1.0M 45,000 shares | -6% | +102% from low-40% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -600 | $89.14 | $53k | 551,940 | 11 d ago |
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,683 | $90.10 | $242k | 549,257 | 11 d ago |
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,638 | $91.49 | $241k | 546,619 | 11 d ago |
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -3,989 | $92.31 | $368k | 542,630 | 11 d ago |
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -4,990 | $93.37 | $466k | 537,640 | 11 d ago |
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -100 | $93.91 | $9,391 | 537,540 | 11 d ago |
| Sep 1, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,500 | $86.36 | $216k | 565,040 | 40 d ago |
| Sep 1, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -8,400 | $87.15 | $732k | 556,640 | 40 d ago |
| Sep 1, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -3,700 | $88.06 | $326k | 552,940 | 40 d ago |
| Sep 1, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -400 | $89.07 | $36k | 552,540 | 40 d ago |
| Mar 23, 2026 | DMRA Galecto, Inc. | AGrant or award Stock Option (right to buy)derivative | +37,313 | $0.00 | $0 | 37,313 | Mar 25, 2026 |
| Mar 2, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -5,900 | $41.73 | $246k | 651,640 | Mar 3, 2026 |
| Mar 2, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -9,100 | $42.49 | $387k | 642,540 | Mar 3, 2026 |
| Feb 2, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -957 | $31.82 | $30k | 671,583 | Feb 4, 2026 |
| Feb 2, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -14,043 | $32.87 | $462k | 657,540 | Feb 4, 2026 |
| Jan 9, 2026 | SYRE Spyre Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +528,000 | $0.00 | $0 | 528,000 | Jan 13, 2026 |
| Jan 2, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -12,709 | $30.47 | $387k | 674,198 | Jan 6, 2026 |
| Jan 2, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,191 | $31.79 | $70k | 672,007 | Jan 6, 2026 |
| Jan 2, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -100 | $32.39 | $3,239 | 671,907 | Jan 6, 2026 |
| Dec 1, 2025 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -10,995 | $28.73 | $316k | 690,912 | Dec 3, 2025 |
| Dec 1, 2025 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -4,005 | $29.83 | $119k | 686,907 | Dec 3, 2025 |
| Nov 3, 2025 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -28,155 | $23.13 | $651k | 718,752 | Nov 5, 2025 |
| Nov 3, 2025 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -16,845 | $23.66 | $399k | 701,907 | Nov 5, 2025 |
| Jun 2, 2025 | ORKA Oruka Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +17,500 | $0.00 | $0 | 17,500 | Jun 3, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.